OR51T1 Antibody

What is OR51T1 and why is it important in research?

OR51T1 (Olfactory Receptor Family 51 Subfamily T Member 1) belongs to the Class I olfactory receptor family, which is part of the G protein-coupled receptor (GPCR) superfamily. These receptors were initially characterized in the olfactory epithelium, but emerging research demonstrates their expression in multiple non-olfactory tissues. As with other ectopically expressed ORs like OR10H1, OR51T1 may have significant roles beyond odorant detection, potentially in cellular signaling pathways relevant to development, tissue homeostasis, or pathological conditions . The OR51 subfamily specifically has been associated with recognition of carboxylic acid ligands, with members ranging from 45% to 74% amino acid identity when compared to consensus sequences . Research interest in OR51T1 stems from its potential involvement in non-canonical signaling pathways and possible roles in disease processes, similar to other characterized ORs.

How do OR51T1 antibodies work and what epitopes do they typically target?

OR51T1 antibodies function by specifically recognizing and binding to unique amino acid sequences (epitopes) in the OR51T1 protein. Commercial polyclonal antibodies like the one described in the search results typically target peptide regions that are both accessible and unique to the target protein. For example, the Boster Bio antibody targets a peptide derived from the human OR51T1 sequence, specifically in the region between amino acids 201-250 . This region likely corresponds to an extracellular or intracellular domain rather than transmembrane segments, as these regions typically offer better antibody accessibility. The antibody-antigen interaction relies on complementary three-dimensional structures and is stabilized by non-covalent interactions including hydrogen bonds, van der Waals forces, and electrostatic interactions. Upon binding, these antibodies can be detected through various methods including direct labeling or secondary antibody systems, allowing visualization or quantification of OR51T1 in experimental systems.

What are the typical applications for OR51T1 antibodies in research?

OR51T1 antibodies serve multiple experimental purposes in olfactory receptor research and beyond:

• Western Blotting (WB): For detecting and quantifying OR51T1 protein in tissue or cell lysates, typically observing a band at approximately 72 kDa despite a calculated molecular weight of approximately 37 kDa . This discrepancy is common with membrane proteins due to post-translational modifications and detergent binding.

• Immunocytochemistry (ICC)/Immunofluorescence (IF): For visualizing cellular and subcellular localization of OR51T1 in cultured cells, providing insights into trafficking and localization patterns.

• ELISA: For quantitative detection of OR51T1 in various sample types.

• Tissue Expression Profiling: Similar to studies with other olfactory receptors like OR10H1, researchers can use OR51T1 antibodies to characterize expression patterns across normal and pathological tissues, potentially identifying ectopic expression sites of interest .

• Functional Studies: When combined with other techniques, OR51T1 antibodies can help elucidate the receptor's role in various cellular processes, similar to how OR10H1 has been studied in bladder cancer tissues .

What are the optimal validation methods to ensure OR51T1 antibody specificity?

Ensuring antibody specificity is critical for reliable results with OR51T1 antibodies. A comprehensive validation approach should include:

• Positive and Negative Controls:

  • Positive: Tissues/cells known to express OR51T1

  • Negative: Tissues/cells lacking OR51T1 expression

  • Overexpression systems: HEK293T cells transfected with OR51T1 expression constructs

  • Knockout or knockdown systems: CRISPR/Cas9 or siRNA methods to ablate OR51T1 expression

• Multiple Detection Methods:

  • Parallel validation using at least two techniques (WB, IF, ICC, ELISA)

  • Correlation with mRNA expression data (RT-PCR, RNA-seq)

• Peptide Competition Assay: Pre-incubation of the antibody with its specific immunogenic peptide should eliminate the specific signal if the antibody is truly specific.

• Cross-Reactivity Testing: Especially important for OR51T1 due to the high sequence homology among olfactory receptors. Testing against closely related ORs (particularly within the OR51 subfamily) is essential to confirm specificity.

• Mass Spectrometry Validation: For absolute confirmation, immunoprecipitation followed by mass spectrometry analysis can verify that the antibody captures the intended target.

This comprehensive approach reflects the validation methods used for other olfactory receptor antibodies, as demonstrated in studies with OR10H1 where specificity was validated in OR10H1-transfected Hana3A cells .

How can I optimize Western blot protocols for accurate OR51T1 detection?

Optimizing Western blot protocols for OR51T1 detection requires addressing the challenges common to membrane protein analysis:

Sample Preparation:

• Use specialized lysis buffers containing appropriate detergents (RIPA or NP-40 with protease inhibitors)

• Avoid boiling samples (heat to 37°C for 30 minutes instead)

• Include reducing agents (β-mercaptoethanol or DTT)

Gel Electrophoresis and Transfer:

• Use 10-12% polyacrylamide gels for optimal separation

• Consider using gradient gels (4-20%) to better resolve the 72 kDa observed band

• Employ wet transfer methods at lower voltage for longer durations (30V overnight at 4°C)

• Use PVDF membranes rather than nitrocellulose for improved protein retention

Antibody Incubation:

• Start with the manufacturer's recommended dilution (1:500 - 1:2000)

• Block thoroughly (5% non-fat milk or BSA in TBST for at least 1 hour)

• Extend primary antibody incubation time (overnight at 4°C)

• Include 0.05% SDS in antibody dilution buffer to reduce non-specific binding

Detection:

• Use enhanced chemiluminescence (ECL) systems with extended exposure times

• Consider fluorescence-based detection for improved quantification

Troubleshooting:

• If multiple bands appear, increase blocking stringency and antibody dilution

• If signal is weak, decrease antibody dilution or increase protein loading

• For high background, increase washing steps (5 x 5 minutes with TBST)

These optimizations address the challenges frequently encountered when working with olfactory receptors, which often express at lower levels than other proteins and may exhibit post-translational modifications.

What controls are essential when using OR51T1 antibodies in immunofluorescence/ICC experiments?

When conducting immunofluorescence or ICC experiments with OR51T1 antibodies, the following controls are essential:

Positive Controls:

• Cells or tissues with confirmed OR51T1 expression (based on RNA-seq or RT-PCR data)

• Transfected cell lines overexpressing epitope-tagged OR51T1

Negative Controls:

• Primary antibody omission (to assess secondary antibody specificity)

• Isotype control (matching IgG at the same concentration)

• Cells with confirmed absence of OR51T1 expression

• OR51T1 knockdown or knockout cells

• Peptide competition (pre-incubation of antibody with immunizing peptide)

Subcellular Localization Controls:

• Co-staining with established subcellular markers:

  • Plasma membrane: Na⁺/K⁺-ATPase or WGA

  • Endoplasmic reticulum: Calnexin or PDI

  • Golgi apparatus: GM130

  • Endosomes: Rab5 or Rab7

Technical Controls:

• Autofluorescence control (unstained sample)

• Single-stained controls (when performing multi-color IF)

• Fixed but not permeabilized samples (to distinguish surface from intracellular staining)

Implementing these controls helps differentiate between specific OR51T1 staining and background signal, particularly important given that olfactory receptors often have relatively low expression levels in heterologous systems, similar to what has been observed with other ORs like those in the OR51 family .

How does OR51T1 compare structurally and functionally with other members of the OR51 subfamily?

OR51T1 belongs to the OR51 subfamily of Class I olfactory receptors, which possess distinct structural and functional characteristics:

Structural Comparison:

Functional Comparison:
OR51T1's functional properties can be inferred by comparison with better-characterized OR51 subfamily members:

• Ligand Preference: As a Class I OR, OR51T1 likely recognizes water-soluble odorants, potentially including carboxylic acids, similar to OR51E1 which responds to pentanoate (pEC50 = -4.64 ± 0.03) . The specific binding profile would be determined by unique residues in the binding pocket.

• Expression Pattern: While some OR51 family members like OR51E1 and OR51E2 show ectopic expression in non-olfactory tissues, including prostate and bladder , OR51T1's specific expression profile requires further characterization.

• Constitutive Activity: Some ORs show constitutive activity (like consOR51), while others require ligand binding for activation. OR51T1's basal activity status depends on specific residues, particularly at positions like 3x37, where bulky aromatic residues increase basal activity .

• G Protein Coupling: Like other OR51 family members, OR51T1 likely couples preferentially to Gαs proteins, activating adenylyl cyclase and increasing cAMP levels, though this remains to be experimentally verified.

Understanding these structural and functional relationships provides critical context for interpreting OR51T1 research findings within the broader framework of olfactory receptor biology.

What methodological approaches can resolve the discrepancy between predicted and observed molecular weights of OR51T1?

The significant discrepancy between the calculated molecular weight of OR51T1 (approximately 37 kDa) and its observed migration on SDS-PAGE (approximately 72 kDa) requires methodological investigation to resolve. This discrepancy is common with membrane proteins, particularly GPCRs, and several approaches can help determine its cause:

1. Investigation of Post-Translational Modifications:

• Glycosylation Analysis:

  • Enzymatic deglycosylation with PNGase F (N-linked) and O-glycosidase (O-linked)

  • Western blot before and after treatment to observe mobility shift

  • Site-directed mutagenesis of predicted N-glycosylation sites (N-X-S/T motifs)

• Phosphorylation Assessment:

  • Alkaline phosphatase treatment

  • Phospho-specific antibodies if available

  • Mass spectrometry analysis to identify phosphorylation sites

• Other Modifications:

  • Palmitoylation (hydroxylamine treatment)

  • Ubiquitination (immunoprecipitation with ubiquitin antibodies)

2. Protein Aggregation and Oligomerization Analysis:

• Sample Preparation Variations:

  • Testing different reducing agents (DTT vs. β-mercaptoethanol)

  • Varying detergent concentrations and types

  • Testing different sample heating conditions

• Crosslinking Studies:

  • Chemical crosslinking to stabilize native oligomeric states

  • Blue native PAGE to analyze non-denatured complexes

3. Technical Approaches to Verify Protein Identity:

• Epitope-Tagged OR51T1 Expression:

  • Transfection of cells with tagged constructs (HA, FLAG, or Myc-tagged OR51T1)

  • Parallel detection with tag-specific and OR51T1-specific antibodies

• Mass Spectrometry Analysis:

  • Immunoprecipitation followed by in-gel digestion

  • Peptide mass fingerprinting to confirm protein identity

• siRNA Knockdown Validation:

  • Demonstrating reduction of the 72 kDa band specifically with OR51T1 siRNA

This comprehensive approach acknowledges that membrane proteins like ORs often display aberrant migration patterns due to their hydrophobic nature, post-translational modifications, and the retention of detergent molecules, similar to observations with other ORs that have been biochemically characterized .

What strategies can overcome the challenges of detecting low-abundance OR51T1 expression in non-olfactory tissues?

Detecting low-abundance OR51T1 in non-olfactory tissues presents significant technical challenges, similar to those encountered with other ectopically expressed ORs. The following integrated approach can enhance detection sensitivity:

1. Sample Enrichment Techniques:

• Subcellular Fractionation:

  • Isolate membrane fractions to concentrate the receptor

  • Differential centrifugation to separate plasma membrane from internal membranes

• Immunoprecipitation:

  • Use validated OR51T1 antibodies for protein enrichment

  • Consider tandem immunoprecipitation with dual antibodies recognizing different epitopes

• Proximity Ligation Assay (PLA):

  • Provides signal amplification for low-abundance proteins

  • Can detect protein-protein interactions if OR51T1 binding partners are known

2. Enhanced Detection Methods:

• Tyramide Signal Amplification (TSA):

  • Enhances IF/IHC detection by up to 100-fold

  • Particularly useful for tissues with low OR51T1 expression

• Highly Sensitive Western Blot Detection:

  • Femto-level chemiluminescent substrates

  • Fluorescence-based Western blotting with near-infrared detection systems

• Quantitative PCR with Pre-Amplification:

  • Target-specific pre-amplification before qPCR

  • Digital droplet PCR for absolute quantification of low-copy transcripts

3. Single-Cell Analysis Techniques:

• Single-Cell RNA-Seq:

  • Identifies cell populations expressing OR51T1 within heterogeneous tissues

  • Avoids dilution effect that occurs in bulk tissue analysis

• Single-Cell Western Blotting:

  • Emerging technology allowing protein analysis at single-cell resolution

4. Transgenic Reporter Systems:

• OR51T1 Promoter-Driven Reporters:

  • Generation of cell lines or model organisms with fluorescent/luminescent reporters under OR51T1 promoter control

  • Enhances sensitivity through enzymatic signal amplification

These approaches have been successful in detecting other low-abundance ORs in non-olfactory tissues, as demonstrated with OR10H1 in bladder cancer tissues where immunohistochemical staining successfully revealed expression patterns even in tissues with relatively low expression levels .

How can OR51T1 antibodies be used to investigate potential roles in cancer research?

Given the emerging evidence that olfactory receptors play roles in cancer biology, OR51T1 antibodies offer valuable tools for cancer research applications. Based on findings with other ORs like OR10H1 in bladder cancer , the following approaches are recommended:

1. Expression Profiling Across Cancer Types:

• Tissue Microarray Analysis:

  • Screening OR51T1 expression across multiple cancer types

  • Correlation with clinical parameters (stage, grade, patient outcomes)

  • Comparison with normal adjacent tissue

• Cancer Cell Line Panel Screening:

  • Western blot and ICC analysis of OR51T1 in diverse cancer cell lines

  • Correlation with cellular phenotypes (proliferation rates, migration capacity)

2. Functional Characterization Studies:

• Knockdown/Knockout Phenotypic Analysis:

  • siRNA or CRISPR-mediated OR51T1 depletion

  • Assessment of effects on proliferation, migration, invasion, and apoptosis

  • Antibodies used to confirm knockdown efficiency

• Pathway Analysis:

  • Immunoprecipitation of OR51T1 to identify binding partners

  • Phosphorylation status analysis after ligand stimulation

  • Co-localization studies with signaling molecules

3. Biomarker Development:

• Liquid Biopsy Applications:

  • Detection of OR51T1 in circulating tumor cells or exosomes

  • Similar to how OR10H1 transcripts were detected in urine samples from bladder cancer patients

• Prognostic/Predictive Marker Assessment:

  • Correlation of OR51T1 levels with treatment response

  • Survival analysis stratified by OR51T1 expression

4. Therapeutic Target Exploration:

• Antibody-Drug Conjugate Development:

  • Utilizing OR51T1 antibodies to deliver cytotoxic payloads specifically to OR51T1-expressing cancer cells

• Function-Blocking Antibody Studies:

  • Development of antibodies targeting extracellular domains that may modulate receptor function

These approaches build on established methodologies used for other ORs in cancer research, where specific expression patterns have led to their investigation as biomarkers and therapeutic targets, as exemplified by OR51E1 and OR51E2 in prostate cancer and OR7C1 in colorectal cancer .

What are the best methodological approaches for investigating OR51T1 ligand binding using antibody-based techniques?

Investigating OR51T1 ligand binding requires specialized methodological approaches that integrate antibody-based techniques with functional assays. Based on successful strategies used with other ORs, the following approaches are recommended:

1. Conformational Change Detection:

• Conformation-Specific Antibodies:

  • Development or identification of antibodies that preferentially recognize active-state OR51T1

  • ELISA or flow cytometry to measure ligand-induced conformational changes

• Protease Protection Assays:

  • Antibody detection of protease-resistant fragments after ligand-induced conformational changes

  • Western blot analysis of fragment patterns before and after ligand exposure

2. Ligand-Receptor Interaction Studies:

• Bioluminescence Resonance Energy Transfer (BRET):

  • OR51T1 fused to luciferase donor

  • Fluorophore-conjugated antibody fragments as acceptors

  • Measurement of energy transfer changes upon ligand binding

• Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET):

  • Antibody-conjugated lanthanide chelates as donors

  • Fluorophore-labeled ligands as acceptors

  • Detection of binding-induced proximity

3. Downstream Signaling Detection:

• Calcium Imaging with Antibody Validation:

  • Parallel antibody staining to confirm OR51T1 expression in responding cells

  • Single-cell correlation of expression level with response magnitude

• cAMP Accumulation Assays:

  • Similar to GloSensor assays used for OR51E1 response to fatty acids (pEC50 = -4.64 ± 0.03 for pentanoate)

  • Antibody-based confirmation of OR51T1 expression levels

4. Structure-Function Relationship Studies:

• Epitope Mapping Combined with Functional Analysis:

  • Panel of antibodies targeting different OR51T1 domains

  • Correlation of epitope accessibility changes with ligand binding

  • Mutational analysis of key residues with antibody detection

These methodologies build on approaches that have successfully identified ligands for other ORs, including OR51E1's response to pentanoate and OR51E2's response to propionate , while incorporating antibody-based techniques to specifically focus on OR51T1 biology.

How can researchers address the cross-reactivity challenges when studying OR51T1 in tissues expressing multiple olfactory receptors?

Cross-reactivity presents a significant challenge when studying OR51T1 due to the high sequence homology among olfactory receptors, particularly within subfamilies. A comprehensive strategy to address this includes:

1. Advanced Antibody Validation:

• Absorption Controls with Related ORs:

  • Pre-incubate OR51T1 antibody with recombinant proteins or peptides from closely related ORs

  • Compare staining patterns before and after absorption

• Heterologous Expression Systems:

  • Test antibody against cells expressing different OR51 family members

  • Create a cross-reactivity profile to understand potential false positives

• Epitope Analysis:

  • Bioinformatic comparison of the immunizing peptide sequence against all OR sequences

  • Focus on antibodies raised against unique regions with minimal homology

2. Complementary Detection Methods:

• RNA-Based Validation:

  • In situ hybridization with OR51T1-specific probes

  • RNAscope technology for single-molecule RNA detection

  • Correlation of protein and mRNA localization patterns

• Genetic Approaches:

  • CRISPR-Cas9 knockout of OR51T1 specifically

  • Rescue experiments with epitope-tagged OR51T1 constructs

  • Analysis of antibody signal in knockout versus wild-type backgrounds

3. Multiplex Detection Strategies:

• Multi-Color Immunofluorescence:

  • Co-staining with antibodies against different ORs

  • Analysis of co-localization versus distinct expression patterns

• Sequential Antibody Labeling:

  • Apply and elute antibodies sequentially on the same sample

  • Digital overlay of images to identify unique versus shared signals

4. Advanced Analytical Approaches:

• Super-Resolution Microscopy:

  • STORM or PALM imaging to precisely localize OR51T1

  • Distinguishing closely related receptors based on subcellular localization

• Mass Cytometry (CyTOF):

  • Metal-tagged antibodies for high-dimensional analysis

  • Distinguishing multiple ORs simultaneously without fluorescence overlap constraints

These approaches acknowledge the challenges encountered in studies of other olfactory receptors, where specificity validation is critical, as demonstrated in the OR10H1 studies where antibody specificity was validated in transfected Hana3A cells .

How can researchers resolve inconsistent OR51T1 antibody performance across different experimental platforms?

Inconsistent antibody performance across different applications (e.g., Western blot versus immunofluorescence) is a common challenge with olfactory receptor antibodies. A systematic troubleshooting approach includes:

1. Epitope Accessibility Analysis:

• Fixation Method Optimization:

  • Compare different fixatives (4% PFA, methanol, acetone)

  • Test varying fixation durations and temperatures

  • Consider antigen retrieval methods for FFPE samples

• Denaturation Conditions:

  • If an antibody works in WB but not ICC, it may recognize a denatured epitope

  • Test different detergent concentrations in ICC protocols

  • Consider mild denaturation steps before antibody application

2. Protocol-Specific Optimization:

3. Antibody Format Considerations:

• Testing Alternative Antibody Formats:

  • If using a polyclonal antibody, consider monoclonal alternatives

  • Test antibodies recognizing different epitopes of OR51T1

  • Consider directly conjugated primary antibodies to eliminate secondary antibody issues

• Storage and Handling Optimization:

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Test freshly reconstituted versus older antibody aliquots

  • Consider additives (BSA, glycerol) to maintain antibody stability

4. Systematic Documentation and Analysis:

• Standardized Reporting:

  • Document exact conditions for successful experiments

  • Create a laboratory-specific validation protocol

  • Implement electronic lab notebook for enhanced reproducibility

The field of olfactory receptor research has faced similar challenges with other receptors, as evidenced by the need for specialized consensus approaches (consORs) to improve expression and detection of these typically difficult-to-study proteins .

What are the most effective strategies to distinguish between specific OR51T1 signal and background in immunohistochemistry?

Distinguishing specific OR51T1 signal from background in immunohistochemistry requires rigorous controls and optimization strategies:

1. Comprehensive Control Panel:

• Essential Negative Controls:

  • Primary antibody omission

  • Isotype-matched irrelevant antibody

  • Peptide competition (pre-absorption with immunizing peptide)

  • OR51T1 knockout or knockdown tissue (if available)

• Positive Controls:

  • Known OR51T1-expressing tissue

  • OR51T1-transfected cells embedded in paraffin

  • Synthetic control slides with recombinant OR51T1 protein

2. Signal-to-Noise Enhancement Techniques:

• Background Reduction Strategies:

  • Endogenous peroxidase quenching (3% H₂O₂ in methanol)

  • Biotin/avidin blocking for biotin-based detection systems

  • Extended serum blocking (2+ hours with 5-10% serum)

  • Addition of 0.1-0.3% Triton X-100 to reduce non-specific binding

• Signal Enhancement Methods:

  • Polymer-based detection systems instead of ABC method

  • Tyramide signal amplification for low-abundance targets

  • Heat-induced epitope retrieval optimization (citrate vs. EDTA buffers)

3. Advanced Analytical Approaches:

• Digital Pathology Tools:

  • Automated image analysis for quantitative assessment

  • Spectral unmixing to distinguish true signal from autofluorescence

  • Machine learning algorithms to classify specific versus non-specific staining patterns

• Multi-Parameter Validation:

  • RNA-scope or in situ hybridization on sequential sections

  • Dual IF with antibodies against OR51T1 and associated signaling molecules

  • Correlation of staining intensity with mRNA expression data

4. Tissue-Specific Considerations:

• Autofluorescence Mitigation:

  • Sudan Black B treatment (0.1-0.3%)

  • Copper sulfate treatment for lipofuscin quenching

  • Spectral imaging and linear unmixing algorithms

These approaches address challenges similar to those encountered in studies of OR10H1 in bladder tissues, where specific staining in carcinoma cells was successfully distinguished from the absence of staining in stromal cells, and validated using transfected cells as controls .

How can researchers develop quantitative assays for measuring OR51T1 expression levels across different tissue samples?

Developing robust quantitative assays for OR51T1 expression requires careful consideration of reference standards, normalization methods, and technical variables:

1. Protein-Based Quantitative Assays:

• Quantitative Western Blotting:

  • Standard curve using recombinant OR51T1 protein

  • Normalization with multiple housekeeping proteins (β-actin, GAPDH, α-tubulin)

  • Fluorescence-based detection for wider linear range

  • Analysis with specialized software (ImageJ, Image Studio Lite)

• Quantitative Flow Cytometry:

  • Antibody validation with OR51T1-transfected and non-transfected controls

  • Calibration with beads containing known antibody binding sites

  • Calculation of molecules of equivalent soluble fluorochrome (MESF)

  • Parallel analysis of cell surface and permeabilized cells

2. mRNA-Protein Correlation Methods:

• RT-qPCR Coupled with Protein Analysis:

  • Absolute quantification using standard curves

  • Calculation of mRNA-to-protein ratios across tissues

  • Assessment of post-transcriptional regulation

• Digital PCR:

  • Absolute quantification without standard curves

  • High sensitivity for low-copy transcripts

  • Correlation with protein levels by Western blot or ELISA

3. Tissue-Level Quantification:

• Quantitative Immunohistochemistry:

  • Digital image analysis of stained tissue sections

  • Automated scoring systems (H-score, Allred score)

  • Normalization to tissue area or cell count

  • Reference standard tissue microarrays for batch correction

• Mass Spectrometry-Based Approaches:

  • Selected reaction monitoring (SRM) for targeted quantification

  • Stable isotope-labeled peptide standards

  • Absolute quantification of OR51T1 protein copy numbers

4. Clinical Sample Considerations:

• Standardized Sample Collection and Processing:

  • Controlled tissue fixation time and conditions

  • Standard operating procedures for sample handling

  • Batch effect corrections in analysis

• Statistical Analysis Framework:

  • Power calculations to determine sample size requirements

  • Appropriate statistical tests for expression differences

  • Multivariate analysis to account for covariates

These quantitative approaches build on methodologies used successfully with other olfactory receptors, such as the quantification of OR10H1 transcripts in urine samples from healthy donors versus bladder cancer patients, where significant differences were detected and statistically analyzed .

How can structural insights from consensus OR research be applied to study OR51T1 functionality?

Recent structural studies using consensus olfactory receptors (consORs) provide valuable frameworks for investigating OR51T1 function:

1. Homology Modeling and Structure Prediction:

• Template Selection and Model Building:

  • Use of consOR51 structure (3.2 Å resolution) as a template for OR51T1 homology modeling

  • Alignment of OR51T1 sequence with consOR51 to identify conserved and variable regions

  • Refinement focusing on the ligand-binding pocket and G-protein interaction interface

• Critical Residue Identification:

  • Analysis of positions equivalent to R264^6x59^ in OR51T1, likely critical for carboxylic acid binding

  • Identification of positions equivalent to F110^3x37^, which influences basal activity

  • Mapping subfamily-specific residues that may confer ligand selectivity

2. Structure-Guided Mutagenesis:

• Rational Design of Functional Mutations:

  • Site-directed mutagenesis of predicted binding pocket residues

  • Creation of chimeric receptors between OR51T1 and better-characterized ORs

  • Introduction of mutations at position 3x37 to modulate basal activity (as demonstrated with consOR51-F110G)

• Function-Structure Correlation:

  • Calcium imaging or cAMP accumulation assays to assess mutant functionality

  • Dose-response analysis for putative ligands

  • Measurement of EC50 shifts with binding pocket mutations

3. Ligand Discovery Approaches:

• Virtual Screening Strategies:

  • Molecular docking of compound libraries to OR51T1 homology models

  • Pharmacophore modeling based on known Class I OR ligands

  • Molecular dynamics simulations to account for receptor flexibility

• Experimental Validation:

  • Functional testing of virtual screening hits

  • Structure-activity relationship analysis of active compounds

  • Determination of binding poses through mutation studies

4. G-protein Coupling Analysis:

• Interaction Interface Studies:

  • Focus on the intracellular regions involved in G-protein coupling

  • Comparison with consOR51-miniGαs fusion protein structure

  • Investigation of potential coupling preferences (Gαs, Gαi, Gαq, Gα12/13)

These approaches leverage the breakthrough structural insights gained from consOR research, where the consensus approach overcame the traditional difficulties in expressing and studying olfactory receptors, enabling structure determination and detailed functional characterization .

What novel biomedical applications could emerge from advanced OR51T1 antibody development?

Advanced OR51T1 antibody development could enable several innovative biomedical applications:

1. Diagnostic and Prognostic Tools:

• Liquid Biopsy Development:

  • Detection of OR51T1 protein in circulating vesicles or tumor cells

  • Development of highly sensitive immunoassays for early disease detection

  • Similar to how OR10H1 transcripts were detected in urine samples from bladder cancer patients

• Tissue-Based Diagnostics:

  • Multiplex immunohistochemistry panels including OR51T1

  • AI-assisted image analysis for pattern recognition

  • Correlation with disease progression and treatment response

2. Therapeutic Applications:

• Antibody-Drug Conjugates (ADCs):

  • OR51T1-targeted delivery of cytotoxic payloads

  • Particularly valuable if OR51T1 shows cancer-specific expression patterns

  • Optimization of linker chemistry and internalization kinetics

• CAR-T Cell Development:

  • Engineering of chimeric antigen receptors based on OR51T1 antibody binding domains

  • Targeting of OR51T1-expressing cancer cells

  • Development of dual-targeting strategies to minimize escape mechanisms

3. Biological Pathway Modulation:

• Function-Blocking Antibodies:

  • Development of antibodies that inhibit OR51T1 signaling

  • Potential therapeutic application in conditions with aberrant OR51T1 activation

  • Similar to approaches targeting other GPCRs in disease states

• Allosteric Modulation:

  • Antibodies targeting extracellular loops that modulate receptor conformation

  • Fine-tuning of signaling responses rather than complete inhibition

  • Potential for biased signaling induction

4. Research and Drug Discovery Tools:

• Proximity-Based Proteomic Analysis:

  • Antibody-based BioID or APEX2 fusion proteins

  • Mapping of OR51T1 protein interaction networks in different cellular contexts

  • Identification of novel therapeutic targets in OR51T1-associated pathways

• Nanobody and Single-Chain Variable Fragment (scFv) Development:

  • Smaller binding molecules for improved tissue penetration

  • Intrabody applications for tracking OR51T1 trafficking in living cells

  • Conformation-specific binders that distinguish active from inactive receptor states

These applications build on emerging approaches in GPCR biology and the growing understanding of olfactory receptors as important signaling molecules beyond their canonical roles in olfaction, as exemplified by the investigation of ORs like OR10H1 in bladder cancer .

How might the study of OR51T1 contribute to our understanding of ectopic olfactory receptor functions in non-olfactory tissues?

Investigating OR51T1 in non-olfactory tissues can significantly advance our understanding of ectopic olfactory receptor functions:

1. Physiological Signaling Network Mapping:

• Downstream Pathway Characterization:

  • Analysis of OR51T1-initiated signaling in non-olfactory tissues

  • Comparison with canonical olfactory signal transduction

  • Investigation of tissue-specific second messenger systems (cAMP, Ca²⁺, other)

  • Exploration of potential roles in ATP and serotonin secretion, similar to those observed with OR10H1

• Receptor Crosstalk:

  • Identification of interactions between OR51T1 and other receptor systems

  • Analysis of OR51T1 involvement in integrating multiple cellular signals

  • Potential compensation mechanisms among related ORs

2. Developmental and Homeostatic Roles:

• Spatiotemporal Expression Mapping:

  • Characterization of OR51T1 expression during embryonic development

  • Analysis of expression changes during tissue differentiation and maturation

  • Comparison with developmental regulation of other OR51 family members

• Functional Perturbation Studies:

  • OR51T1 knockout/knockdown effects on tissue development and homeostasis

  • Rescue experiments with wild-type and mutant OR51T1

  • Long-term consequences of OR51T1 signaling modulation

3. Pathophysiological Implications:

• Disease-Associated Expression Changes:

  • Comprehensive analysis across disease states (cancer, inflammation, degeneration)

  • Correlation with disease progression and severity

  • Potential as a disease biomarker, similar to OR51E1 and OR51E2 in prostate cancer

• Mechanistic Contributions to Disease:

  • Investigation of OR51T1's effects on cell proliferation, similar to OR51B4 in colorectal cancer

  • Analysis of impacts on cell migration and invasion

  • Examination of influences on apoptosis and cell survival pathways

4. Evolutionary and Comparative Biology Insights:

• Cross-Species Comparison:

  • Analysis of OR51T1 orthologs across species

  • Correlation of expression patterns with species-specific physiological requirements

  • Insights into evolutionary repurposing of olfactory signaling machinery

These investigations would contribute to the growing understanding of ectopic OR functions, building on discoveries like OR10H1's role in bladder cancer, OR1A2's reduction of cell proliferation in hepatocellular carcinoma when activated by (-)-Citronellol, and OR51B4's effects on reducing cell proliferation and migration in colorectal cancer , revealing a broader physiological significance of olfactory receptors beyond their canonical roles in odorant detection.